International Dermatology Outcome Measures (IDEOM): Report from the 2021 Annual Meeting [0.03%]
国际皮肤病结局指标(IDEOM)：2021年年度会议报告
Caterina Zagona-Prizio,Jenna Yousif,Carly Grant et al.
Caterina Zagona-Prizio et al.
Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization founded in 2013. It is composed of researchers and stakeholders who work to develop evidenced-based outcome measures to enhance r...
Onset of Plaque Psoriasis Treatment Responses With Anti-IL-17/IL-23 Biologic Therapies [0.03%]
抗IL-17/IL-23生物制剂治疗银屑病起效时间的系统评价和 meta 分析
Richard Fried,Mark Lebwohl,Miriam Bettencourt et al.
Richard Fried et al.
Background: The impact of psoriasis on quality of life arises from both physical symptoms, such as pain and pruritus, and the psychosocial effects of the often highly visible lesions. For patients with moderate-to-severe ...
Treatment of Scalp Psoriasis [0.03%]
头皮银屑病的治疗
Rabia Ghafoor,Anant Patil,Paul Yamauchi et al.
Rabia Ghafoor et al.
Scalp involvement is seen in a majority of individuals with psoriasis, a chronic autoimmune skin disease with variable phenotypes. Occasionally, isolated scalp involvement is observed; and this causes significant psychosocial morbidity. Man...
Usage of Topical Calcineurin Inhibitors in the Medicare Population from 2013 to 2018 [0.03%]
2013至2018年美国医疗保险人群中局部钙调神经磷酸酶抑制剂的使用情况
Christine Learned,Sara Alsukait,David Rosmarin
Christine Learned
Topical calcineurin inhibitors are a family of drugs that have been touted for having high efficacy without the risks of cutaneous atrophy and systemic absorption seen with topical corticosteroids. They may play an important role in the eld...
A Roadmap for the Development of a Diverse and Inclusive Medical Student Dermatologic Curriculum [0.03%]
促进皮肤病学课程多元化和包容性的路线图
Eman Hijab,Marissa Baranowski,Jamie MacKelfresh et al.
Eman Hijab et al.
The need for diversification in dermatology has been increasingly highlighted. However, until recently there had been a lack of emphasis on the pathway that unites all physicians: medical education. Fortunately, current articles have begun ...
Deede Liu,Hythem Abouodah,Daniel Aires
Deede Liu
Options to prevent facial insect bites while sleeping are limited. Patients may prefer to avoid facial application of potentially neurotoxic insect repellants. Non-toxic “natural” repellants have limited efficacy, and netting ma...
"I'm Off My Meds": Public Perception of Interactions Between SARS-CoV-2 Vaccines and Anti-Psoriatic Treatments Online [0.03%]
“我不再服药”：新冠肺炎疫苗与抗银屑病药物互作的公众认知
Danielle Yee,Rasika Reddy,Sabrina Khan et al.
Danielle Yee et al.
Importance: Psoriasis patients may seek information about the SARS-CoV-2 vaccine and their diagnosis from social media platforms. Analyses of social media interactions may help guide dermatologists’ educational effo...
Pediatric Verrucous Psoriasis: A Case Report in a Pediatric Patient and Discussion of the Literature [0.03%]
儿童疣状银屑病一例及文献讨论
Samantha Sherkin,Christian Summa,David Crasto et al.
Samantha Sherkin et al.
Verrucous psoriasis (VP) is a rare histologic variant of psoriasis. To date, fewer than 40 cases have been reported, with pediatric cases representing an exceedingly small fraction. Treatment options are limited, and the disease is often re...
Post-Residency Training Instead of Medical Student Research Fellowships Will Improve Dermatology Patient Care and Excellence [0.03%]
住辛而非医学学生研究奖学金会改进皮肤病患者的治疗状况及卓越度
Shari Lipner,Julianne Falotico
Shari Lipner
Research fellowships among prospective dermatology residency applicants are becoming increasingly popular. These fellowships provide opportunities for mentorship, publications, and clinical experience, but unpaid positions impose a signific...
Single-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis [0.03%]
格塞库单抗治疗中重度斑块状银屑病的单中心真实世界研究经验
Dario Marletta,Giulia Murgia,Angelo Cattaneo et al.
Dario Marletta et al.
The efficacy of guselkumab has been demonstrated in randomized controlled trials, but real-life data are still missing. This study presents a single-center real-life experience in treating moderate-to-severe plaque psoriasis with guselkumab...